The short answer
Radioimmunoassay quantifies how much material in a sample competes with a labelled standard for antibody binding. It measures immunoreactivity, which is what an antibody recognises, not necessarily the molecule the antibody was raised against.
Key facts
- Measures
- Competition for antibody binding
- Reports
- Immunoreactivity
- Does not establish
- Molecular identity
- Cross-reactivity
- Any molecule sharing the epitope
- Standard hedge
- '-like material', 'immunoreactive X'
- Confirmation requires
- Chromatography, mass spectrometry
How the method works
A known quantity of labelled peptide and an antibody are mixed with the sample. Anything in the sample that binds the antibody displaces some labelled peptide, and the amount displaced is converted into a concentration. It is sensitive, it scales well, and it was the workhorse of peptide endocrinology for decades.
What the antibody actually recognises
An epitope, a small region of the molecule, often only a handful of residues. Anything presenting that region will bind, whether it is the intended peptide, a fragment containing it, a larger precursor, or an unrelated molecule that happens to display a similar surface. The assay cannot distinguish between them, because binding is all it measures.
Research material referenced
DSIP 5mg, third-party HPLC tested
Why the hedged phrasing exists
Careful authors write DSIP-like material or immunoreactive DSIP rather than DSIP. That is not stylistic caution. It is a precise statement that the assay detected something the antibody bound, and that identity was not established. Where a paper uses the hedge and a summary of it drops the hedge, the claim has been strengthened without any new evidence.
How the ambiguity gets resolved
By separating the sample before measuring it. Chromatography sorts material by size, so running immunoreactive fractions on a column shows whether the signal sits where the peptide should. If it appears at a much larger size, the antibody is binding something else. Mass spectrometry settles identity outright.
Why this matters for the DSIP literature specifically
Most of the tissue distribution work behind this compound's reputation was generated by radioimmunoassay in the 1980s. Whether those measurements identified the peptide or a family of larger molecules sharing an epitope is a question the method cannot answer on its own, and one the original authors examined directly.
What this is not
A criticism of the technique or of the researchers who used it. Radioimmunoassay was and is a legitimate and sensitive method, and the people who used it generally stated its limits accurately. The problem arises downstream, where careful phrasing is discarded by people summarising the work.
Frequently asked questions
What does a radioimmunoassay measure?
How much material competes with a labelled standard for antibody binding, immunoreactivity, not molecular identity.
Why do papers say 'DSIP-like material'?
It is a precise hedge meaning the antibody bound something, and identity was not established.
How is identity confirmed?
Chromatography to check the signal appears at the right size, and mass spectrometry to settle it outright.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedGraf MV, Kastin AJ, Delta sleep-inducing peptide (DSIP)-like material exists in peripheral organs of rats in large dissociable forms. Proc Soc Exp Biol Med 1984 (PMID 6548030)pubmed.ncbi.nlm.nih.gov
- PubMedBjartell A et al., Immunoreactive delta sleep-inducing peptide in the rat hypothalamus, pituitary and adrenal gland. Horm Res 1991 (PMID 1814802)pubmed.ncbi.nlm.nih.gov
- PubMedGraf MV, Delta-sleep-inducing peptide (DSIP): an update. Peptides 1986 (PMID 3550726)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More DSIP (Delta Sleep-Inducing Peptide) articles
- What the Antibody Found in Peripheral TissueGraf and Kastin measured DSIP-like material across 12 rat tissues - highest in stomach - then showed chromatography put most of it at a larger size.
- What Adrenalectomy ChangedBjartell 1991 measured immunoreactive DSIP in rat hypothalamus, pituitary and adrenal gland, and examined what removing the adrenals did to it.
- A Question Mark in the Title Is Doing Real WorkGimble 2009 proposed links between DSIP, glucocorticoid-induced leucine zipper, circadian mechanisms and obesity - and framed it as a question.
- What the Field Said After Its First DecadeGraf published a DSIP update in Peptides in 1986. Reading a review from the middle of a literature shows what was expected but never arrived.
- The Barrier Any Central Claim Has to CrossA compound said to act on sleep must reach the brain. The blood-brain barrier excludes most peptides, and getting across is an engineering problem.